Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Pallidotomy improves motor responses and widens the levodopa therapeutic window in Parkinson's disease.

Identifieur interne : 005026 ( Ncbi/Curation ); précédent : 005025; suivant : 005027

Pallidotomy improves motor responses and widens the levodopa therapeutic window in Parkinson's disease.

Auteurs : E J Skalabrin [États-Unis] ; E R Laws ; J P Bennett

Source :

RBID : pubmed:9756145

English descriptors

Abstract

Stereotactic posteroventral pallidotomy (PVP) as a treatment for Parkinson's disease (PD) symptoms has been increasingly used in moderate-advanced disease. We examined the pharmacodynamic responses of PD patients to single oral levodopa doses and intravenous levodopa infusions before and after PVP surgery. Nine subjects with advanced PD received a single oral dose and ramped intravenous levodopa infusions before and 3-5 weeks after unilateral PVP. Timed motor tasks, Unified Parkinson's Disease Rating Scale (UPDRS) evaluations, and ordinal dyskinesia rating were performed after oral levodopa and during i.v. levodopa infusions. Serum prolactin and dopa levels were measured during the levodopa infusions. Overall timed motor but not motor UPDRS scores were improved after PVP in both the worst ("off") and best ("on") states. Contralateral but not ipsilateral limb dyskinesias were substantially reduced at all serum (dopa) levels after PVP. Ipsilateral and contralateral timed motor performance at low serum (dopa) levels was improved by PVP. Walking speeds at all serum (dopa) levels were not changed by PVP. Serum prolactin was reduced equally by increasing (dopa) preoperatively and postoperatively. PVP significantly and favorably altered oral and intravenous levodopa pharmacodynamics by improving bilateral limb motor function and contralateral dyskinesia but did not alter walking speed. PVP appears to widen significantly the therapeutic window for levodopa in PD.

DOI: 10.1002/mds.870130504
PubMed: 9756145

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:9756145

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Pallidotomy improves motor responses and widens the levodopa therapeutic window in Parkinson's disease.</title>
<author>
<name sortKey="Skalabrin, E J" sort="Skalabrin, E J" uniqKey="Skalabrin E" first="E J" last="Skalabrin">E J Skalabrin</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Neurology, University of Virginia Health Sciences Center, Charlottesville 22908, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Virginia Health Sciences Center, Charlottesville 22908</wicri:regionArea>
<wicri:noRegion>Charlottesville 22908</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Laws, E R" sort="Laws, E R" uniqKey="Laws E" first="E R" last="Laws">E R Laws</name>
</author>
<author>
<name sortKey="Bennett, J P" sort="Bennett, J P" uniqKey="Bennett J" first="J P" last="Bennett">J P Bennett</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="1998">1998</date>
<idno type="RBID">pubmed:9756145</idno>
<idno type="pmid">9756145</idno>
<idno type="doi">10.1002/mds.870130504</idno>
<idno type="wicri:Area/PubMed/Corpus">004339</idno>
<idno type="wicri:Area/PubMed/Curation">004339</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004371</idno>
<idno type="wicri:Area/Ncbi/Merge">005026</idno>
<idno type="wicri:Area/Ncbi/Curation">005026</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Pallidotomy improves motor responses and widens the levodopa therapeutic window in Parkinson's disease.</title>
<author>
<name sortKey="Skalabrin, E J" sort="Skalabrin, E J" uniqKey="Skalabrin E" first="E J" last="Skalabrin">E J Skalabrin</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Neurology, University of Virginia Health Sciences Center, Charlottesville 22908, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, University of Virginia Health Sciences Center, Charlottesville 22908</wicri:regionArea>
<wicri:noRegion>Charlottesville 22908</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Laws, E R" sort="Laws, E R" uniqKey="Laws E" first="E R" last="Laws">E R Laws</name>
</author>
<author>
<name sortKey="Bennett, J P" sort="Bennett, J P" uniqKey="Bennett J" first="J P" last="Bennett">J P Bennett</name>
</author>
</analytic>
<series>
<title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="1998" type="published">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Administration, Oral</term>
<term>Aged</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Combined Modality Therapy</term>
<term>Dihydroxyphenylalanine (blood)</term>
<term>Dominance, Cerebral (drug effects)</term>
<term>Dominance, Cerebral (physiology)</term>
<term>Female</term>
<term>Gait (drug effects)</term>
<term>Globus Pallidus (physiopathology)</term>
<term>Globus Pallidus (surgery)</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Levodopa (administration & dosage)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Motor Skills (drug effects)</term>
<term>Motor Skills (physiology)</term>
<term>Neurologic Examination (drug effects)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson Disease (surgery)</term>
<term>Prolactin (blood)</term>
<term>Stereotaxic Techniques</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en">
<term>Dihydroxyphenylalanine</term>
<term>Prolactin</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Dominance, Cerebral</term>
<term>Gait</term>
<term>Motor Skills</term>
<term>Neurologic Examination</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Dominance, Cerebral</term>
<term>Motor Skills</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en">
<term>Globus Pallidus</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en">
<term>Globus Pallidus</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Administration, Oral</term>
<term>Aged</term>
<term>Combined Modality Therapy</term>
<term>Female</term>
<term>Humans</term>
<term>Infusions, Intravenous</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Stereotaxic Techniques</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Stereotactic posteroventral pallidotomy (PVP) as a treatment for Parkinson's disease (PD) symptoms has been increasingly used in moderate-advanced disease. We examined the pharmacodynamic responses of PD patients to single oral levodopa doses and intravenous levodopa infusions before and after PVP surgery. Nine subjects with advanced PD received a single oral dose and ramped intravenous levodopa infusions before and 3-5 weeks after unilateral PVP. Timed motor tasks, Unified Parkinson's Disease Rating Scale (UPDRS) evaluations, and ordinal dyskinesia rating were performed after oral levodopa and during i.v. levodopa infusions. Serum prolactin and dopa levels were measured during the levodopa infusions. Overall timed motor but not motor UPDRS scores were improved after PVP in both the worst ("off") and best ("on") states. Contralateral but not ipsilateral limb dyskinesias were substantially reduced at all serum (dopa) levels after PVP. Ipsilateral and contralateral timed motor performance at low serum (dopa) levels was improved by PVP. Walking speeds at all serum (dopa) levels were not changed by PVP. Serum prolactin was reduced equally by increasing (dopa) preoperatively and postoperatively. PVP significantly and favorably altered oral and intravenous levodopa pharmacodynamics by improving bilateral limb motor function and contralateral dyskinesia but did not alter walking speed. PVP appears to widen significantly the therapeutic window for levodopa in PD.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005026 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 005026 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:9756145
   |texte=   Pallidotomy improves motor responses and widens the levodopa therapeutic window in Parkinson's disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i   -Sk "pubmed:9756145" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3 

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024